Copyright © 2021 Pharmascimed. All Rights Reserved.
Akcea therapeutics
- Home
- Akcea therapeutics
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Novartis has acquired rights to TQJ230 from Akcea Therapeutics, a novel cardiovascular drug that could become first-in-class and has the potential to treat million of patients. TQJ230 is based on the...
Read moreTrending
Recent Posts
The coming age of biosimilars
- February 26, 2019
- 0
Novartis acquires game-changing cardiovascular therapy
- February 25, 2019
- 0
Roche buys gene therapy company Spark for $4.3bn
- February 25, 2019
- 0
AbbVie and Voyager Therapeutics in Parkinson’s Pact
- February 22, 2019
- 0